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Abstract
Background
Immune infiltration of breast tumours is associated with clinical outcome. However, past
work has not accounted for the diversity of functionally distinct cell types that make up the
immune response. The aim of this study was to determine whether differences in the cellular
composition of the immune infiltrate in breast tumours influence survival and treatment
response, and whether these effects differ by molecular subtype.
Methods and Findings
We applied an established computational approach (CIBERSORT) to bulk gene expression
profiles of almost 11,000 tumours to infer the proportions of 22 subsets of immune cells. We
investigated associations between each cell type and survival and response to chemother-
apy, modelling cellular proportions as quartiles. We found that tumours with little or no
immune infiltration were associated with different survival patterns according to oestrogen
receptor (ER) status. In ER-negative disease, tumours lacking immune infiltration were
associated with the poorest prognosis, whereas in ER-positive disease, they were associ-
ated with intermediate prognosis. Of the cell subsets investigated, T regulatory cells and M0
and M2 macrophages emerged as the most strongly associated with poor outcome, regard-
less of ER status. Among ER-negative tumours, CD8+ T cells (hazard ratio [HR] = 0.89,
95% CI 0.80–0.98; p = 0.02) and activated memory T cells (HR 0.88, 95% CI 0.80–0.97;
p = 0.01) were associated with favourable outcome. T follicular helper cells (odds ratio
[OR] = 1.34, 95% CI 1.14–1.57; p < 0.001) and memory B cells (OR = 1.18, 95% CI 1.0–
1.39; p = 0.04) were associated with pathological complete response to neoadjuvant chemo-
therapy in ER-negative disease, suggesting a role for humoral immunity in mediating
response to cytotoxic therapy. Unsupervised clustering analysis using immune cell propor-
tions revealed eight subgroups of tumours, largely defined by the balance between M0, M1,
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and M2 macrophages, with distinct survival patterns by ER status and associations with
patient age at diagnosis. The main limitations of this study are the use of diverse platforms
for measuring gene expression, including some not previously used with CIBERSORT, and
the combined analysis of different forms of follow-up across studies.
Conclusions
Large differences in the cellular composition of the immune infiltrate in breast tumours
appear to exist, and these differences are likely to be important determinants of both prog-
nosis and response to treatment. In particular, macrophages emerge as a possible target
for novel therapies. Detailed analysis of the cellular immune response in tumours has the
potential to enhance clinical prediction and to identify candidates for immunotherapy.
Author Summary
Why Was This Study Done?
• Previous studies have shown that certain immune cells present in breast tumours are
associated with risk of relapse.
• Whether particular immune cell types are associated with a greater or lesser risk of
relapse, however, and how these effects differ by breast cancer subtype, remains unclear.
What Did the Researchers Do and Find?
• We conducted a large analysis of breast tumour gene expression profiles available in the
public domain (10,988 cases) to derive estimates of the relative proportions of 22 subsets
of immune cells, in order to investigate associations between the proportion of each cell
type and disease relapse or response to chemotherapy.
• We found that higher proportions of some immune cell types were associated with
greater risk of relapse (or greater chemotherapy response), whereas others were associ-
ated with lesser risk, and that these associations were often different according to the
oestrogen receptor (ER) status of the tumour.
• In tumours lacking expression of ER, we found that the presence of CD8+ T cells and
activated memory T cells was associated with a reduction in the risk of relapse, while
tumours with high proportions of T follicular helper cells were more likely to respond
to neoadjuvant chemotherapy.
• In ER-positive tumours, the presence of M0 macrophages was associated with poor
prognosis.
• T regulatory cells were associated with poor prognosis in both ER-positive and ER-neg-
ative tumours.
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What Do These Findings Mean?
• These findings establish a complex relationship between the heterogeneity of intratu-
moural immune cells, tumour molecular subtype, and disease progression in breast
cancer.
• Treatments that aim to boost the immune response to tumours, i.e., immunotherapies,
are effective in only a subset of patients, and our findings may help to identify this
patient group and suggest targets for the development of new immunotherapies.
Introduction
Breast cancer is characterised by biological and clinical diversity. Genomic changes in cancer
cells have been extensively investigated to identify patient subgroups with different prognoses
and different responses to treatment, as well as to find new drug targets [1–3]. However, breast
tumours are composed of intimate mixtures of cancer cells and non-cancer cells. The roles of
these non-cancer cells remain poorly understood. Non-cancer cells compose varying propor-
tions of tumours and include stromal cells, vascular cells, and infiltrating immune cells. Of
these, infiltrating immune cells seem the most likely to improve the prediction of clinical out-
come and to be effectively targeted by drugs. This is because recent trials of drugs that target
immune checkpoints [4–7]—physiological pathways that regulate the immune response to self
as well as immune response duration and severity in disease—have shown that they can signifi-
cantly prolong the survival of a subset of patients with solid tumours including melanoma,
non-small-cell lung carcinoma, renal cell carcinoma [5], and, most recently, triple-negative
breast cancer [6]. Also, past studies have shown that the immune response is associated with
both clinical outcome and response to treatment in breast cancer [8–13]. Owing to technical
limitations, these studies have necessarily been limited to a very narrow view of the immune
response, generally including only one or two cell types. The immune response, however, is
characterised by numerous specialised cell types that interact in a highly coordinated manner.
To better understand the nature and diversity of the immune response to breast tumours, it is
therefore necessary to enumerate immune cells in a way that accounts for the breadth of their
specialised functions. In addition, to reliably investigate the interaction of the immune
response with different molecular subtypes of breast cancer, it is also necessary to analyse very
large cohorts of patients encompassing the molecular diversity of the disease.
The aim of this study was to quantify the cellular composition of the immune response in
breast tumours in order to investigate its relationship with molecular subtype, survival, and
response to chemotherapy. We applied a recently described gene expression deconvolution
algorithm (CIBERSORT) [14], which estimates the relative proportions of 22 distinct func-
tional subsets of immune cells, to almost 11,000 breast tumour transcriptomes with clinical
annotation and data in the public domain.
Methods
Gene Expression Datasets
This study made use of data in the public domain. Details of ethical approval and patient con-
sent for all 56 studies can be found in their corresponding publications specified in S1 Table.
In total, 56 studies were included, of which 32 were compiled and curated by Haibe-Kains
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et al. (data available at http://compbio.dfci.harvard.edu/pubs/sbtpaper/) as previously
described [15]. Additional studies were downloaded from Gene Expression Omnibus and
ArrayExpress. Data from The Cancer Genome Atlas (TCGA) were downloaded from the
TCGA data portal in April 2016. All studies with gene expression data from primary breast
tumours were considered eligible, with no specific exclusion criteria applied. One study was
removed because the article had since been retracted [16]. Studies are summarised, together
with accession numbers, in S1 Table. Cases identified as replicates by Haibe-Kains et al. were
removed (n = 181). Samples with the same accession identifier were also removed (n = 697).
Further replicates were identified by computing Pearson correlations between all samples aris-
ing from the same centre. Samples with Pearson correlations of 0.99 or greater were consid-
ered replicates (n = 248). Where replicate cases were identified, all but one record were
removed from further analysis. In total, 10,988 cases were available for analysis following
removal of replicate records. Details of which samples were included at each stage of analysis
are illustrated in Fig 1 as a flowchart. Each tumour sample corresponded to one patient. No
protocol or prospective analysis plan was specified for the study.
Molecular Subtyping and Inference of Infiltrating Immune Cells
Oestrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) status were
preferentially determined by study annotation. Where unavailable, normalised gene expres-
sion data were used to infer probable ER or HER2 status using a two-component Gaussian
finite mixture model using maximum likelihood estimation on a per-study basis, in a manner
similar to that previously described [17]. Where more than one probe was available for either
gene, the probe associated with the highest log-likelihood from the mixture regression model
was used. Whether inferred receptor status was considered sufficiently reliable for analysis was
determined by examining histograms of the distribution of expression values and the relative
proportions of inferred positive and negative tumours. Where the distribution of expression
data clearly departed from two Gaussian distributions or where inferred proportions of posi-
tive and negative status were judged implausible based on study annotation, inferred ER and
HER2 status was not used in further analysis.
Classification into the ten IntClust molecular subtypes was achieved based on gene expres-
sion data using the iC10 package [18] in R, as previously described [2]. Distributions of molec-
ular and clinical characteristics by study are detailed in S2 Table.
Normalised gene expression data were used to infer the relative proportions of 22 types of
infiltrating immune cells using the CIBERSORT algorithm. For the TCGA dataset [3], RNA
sequencing data were transformed using voom [19] (variance modelling at the observational
level), converting count data to values more similar to those resulting from microarrays. The
22 cell types inferred by CIBERSORT encompass B cells, T cells, natural killer cells, macro-
phages, dendritic cells, eosinophils, and neutrophils, amongst others. CIBERSORT is a decon-
volution algorithm that uses a set of reference gene expression values (a “signature matrix” of
547 genes) considered a minimal representation for each cell type and, based on those values,
infers cell type proportions in data from bulk tumour samples of mixed cell types using sup-
port vector regression [14]. CIBERSORT derives a p-value for the deconvolution for each sam-
ple using Monte Carlo sampling, providing a measure of confidence in the results. Gene
expression datasets were prepared using standard annotation files and data uploaded to the
CIBERSORT web portal (http://cibersort.stanford.edu/), with the algorithm run using the
default signature matrix at 1,000 permutations. Since we pooled numerous studies published
over some years, the technologies used to measure gene expression differed substantially, with
variable representation of the 547 genes that comprise the signature matrix. In order to
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estimate the effect of this variable representation, we used 100 cases from the METABRIC
study, where 87% of the genes are represented. We randomly deleted signature matrix genes in
increments of 10% (55 genes) until 7% of genes remained to produce a graded representation
Fig 1. Study flowchart detailing the flow of samples at each stage of analysis. *[15]. †[16]. ER, oestrogen
receptor; pCR, pathological complete response; MI, multiple imputation; TGCA, The Cancer Genome Atlas.
doi:10.1371/journal.pmed.1002194.g001
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of signature matrix genes. We ran CIBERSORT across these conditions and compared the out-
put. Immune cytolytic activity representing the geometric mean of GZMA and PRF1 is another
in silico measure of immune infiltration, as described by Rooney et al. [20]. Immune cytolytic
activity for the TCGA dataset was used, as provided in the supplement of Rooney et al. [20],
and was calculated for the METABRIC study as the geometric mean of GZMK and PRF1.
Statistical Analyses
Associations between inferred proportions of immune cell types and survival were tested using
Cox regression. Analyses were conducted separately for ER-negative and ER-positive disease
to account for this fundamental difference in breast cancer and for known violations of the
Cox proportional-hazards assumption [21]. Cox regression analyses were stratified by study,
with the five contributing centres of the METABRIC [1] study considered separate strata.
Although the diversity of studies included meant that different types of follow-up were
recorded, a single survival time variable was generated to enable derivation of more precise
estimates owing to larger sample size. Where more than one type of follow-up was available,
the following hierarchy was used to select one: (1) relapse-free survival, (2) distant metastasis-
free survival, (3) disease-specific survival, and (4) overall survival. The type of survival time
available for each study is detailed in S1 Table. Survival analyses were truncated at 15 y. Cases
with a CIBERSORT p-value of<0.05 were included in the main survival analysis. Quartiles of
the proportion of each cell type were computed for survival analysis and modelled as continu-
ous variables in order to derive more easily interpretable hazard ratios (HRs). Quartiles were
calculated separately by ER status or relevant subgroup. Where all samples were included in
analyses irrespective of CIBERSORT p-value, cases with an empirical CIBERSORT p 0.05
formed a separate baseline reference category to which the quartiles of proportion, based on
cases with an empirical CIBERSORT p< 0.05, were compared, yielding five groups in total (0:
all cases with a CIBERSORT p 0.05, 1–4: quartiles of immune cell proportion for remaining
cases with a CIBERSORT p< 0.05). Heterogeneity of estimates in subgroup analyses was
tested using Cochran’s Q test. Where subgroup analyses comprised both ER-positive and ER-
negative tumours, models were adjusted for ER status and an interaction term allowed to vary
as a function of the logarithm of time included, accounting for violations of the proportional-
hazards assumption. Interaction terms between ER and cell type proportion were included in
Cox regression models to evaluate differences in effect by ER status. Immune cell subsets sig-
nificantly associated with outcome in unadjusted analyses were included in multivariable
models. Multivariable analyses were adjusted for lymph node status (negative, positive),
tumour size (<10 mm, 10–19 mm, 20–29 mm, 30–49 mm, 50+ mm), histological grade, and
HER2 status. Ordinal categories of tumour size and histological grade were modelled as con-
tinuous variables. The log-rank statistic was used to assess differences in survival between
groups as depicted in Kaplan-Meier survival plots. Analyses complied with STROBE criteria
[22]. A STROBE checklist is provided as S3 Table.
To assess the association between different immune cell types and response to chemother-
apy, we used data from studies of neoadjuvant chemotherapy (where patients received chemo-
therapy before surgery). The endpoint of these studies was pathological complete response
(pCR). Although there is some variation in the definition of pCR, it usually refers to the com-
plete elimination of cancer cells, as assessed by careful histology of the primary tumour bed fol-
lowing surgery. Associations between different immune cell types and pCR were assessed by
logistic regression. Quartiles of proportions of each immune cell type were modelled as contin-
uous variables. Analyses were conducted separately by ER status, since ER itself is strongly
associated with pCR [23]. Multivariable analyses were adjusted by lymph node stage, tumour
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stage, histological grade, and HER2 status. Ordinal categories of node stage, tumour stage, and
grade were modelled as continuous variables.
We addressed the possibility of selection bias due to missing data in multivariable models
by deriving estimates based on multiply imputed datasets. Multiple imputation is a method for
inferring the probable values of missing covariables repeatedly across several datasets, then
deriving estimates for each dataset, and finally combining estimates in a manner that accounts
for the variability between and within datasets. We imputed clinical covariables (tumour size
or T stage, node status or N stage, grade, and HER2 status) across fifty datasets using the ice
command in Stata [24]. Datasets were imputed separately for survival analyses and analyses of
pCR. Quartiles of all immune cell subsets and clinical covariables were included in imputation
models. An outcome variable was included for both survival imputation models (Nelson-
Aalen cumulative hazard estimator and an outcome indicator variable) and pCR imputation
models (pCR) [25]. Estimates were combined using Rubin’s rules.
We further addressed the possibility that variable selection based on univariable analysis
may lead to exclusion of some variables that may be associated with outcome when confound-
ing is properly controlled [26]. We accounted for the possibility of confounding by all immune
cell subsets and clinical variables by fitting multivariable models (26 predictors) via penalised
maximum likelihood using the package glmnet [27] with the penalisation factor selected based
on cross-validation.
Associations between continuous and categorical variables were tested using the Kruskal-
Wallis test. Correlations between immune cell subsets were evaluated using the Pearson corre-
lation coefficient. For univariable analyses of the 22 immune cell subsets, adjustment for multi-
ple testing was conducted by calculating q-values using the Benjamini-Hochberg method.
To investigate whether distinct classes of immune cell infiltration are present in different
tumours and whether these classes are associated with different clinical outcome, we con-
ducted hierarchical clustering of immune cell proportions. Values were rescaled to lie between
zero (for the smallest value observed) and one (for the greatest value observed) for each cell
type to ensure comparability between rare (low overall proportion) and abundant (high overall
proportion) cell types. Hierarchical clustering of these data by Ward’s method was conducted
across all samples. A combination of the Duda-Hart index and the associated pseudo-T-
squared statistic was used to explore the likely number of distinct clusters in the data. The asso-
ciations between clusters and clinical outcome were tested using the methods described above.
All analyses were conducted using R version 3.3 [28] or Stata SE version 14.1 (StataCorp).
The complete dataset used for all analyses is available at https://github.com/cclab-brca.
Results
Performance of CIBERSORT across Studies
Fig 2A depicts a summary of the 56 included studies, totalling 10,988 cases of breast cancer.
Gene expression was measured using a variety of platforms, as detailed in S1 Table. S1 Fig
depicts the proportion of the 547 genes composing the signature matrix that were available
for analysis by study. The mean number of genes represented was 447 (range 12–529). S2 and
S3 Figs depict comparative summaries of CIBERSORT output across 100 cases from the
METABRIC study where signature matrix genes were randomly deleted in increments of 10%
(55 genes). S2 Fig shows that the empirical CIBERSORT p-value was highly sensitive to dimin-
ishing representation of the signature matrix, with over half of the samples (n = 53) with a
CIBERSORT p< 0.05 at 87% representation but none at27% representation. However, of
the samples associated with p< 0.05, inferred cell proportions showed relatively small differ-
ences (S3 Fig), although this differed by cell type. These findings imply that, while variable
Patterns of Immune Infiltration in Breast Cancer
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representation of the signature matrix inevitably influences the accuracy of the inferred
immune cell populations, this effect is not large when analyses are limited to cases with a
CIBERSORT p< 0.05. At a threshold of CIBERSORT p< 0.05, 55% of samples (6,071/10,988)
yielded data on infiltrating immune cells, while at a threshold of p< 0.01, 40% (4,385/10,988)
of samples yielded data. Unless otherwise specified, analyses were restricted to samples with a
CIBERSORT p< 0.05. Of these samples, the least variable cell type between studies was eosin-
ophils (0%–3%), while the most variable was plasma cells (<1%–27%).
CIBERSORT p-Values Reflect the Overall Proportion of Immune Cells
There were large differences in the proportions of samples at different p-value thresholds
between studies, spanning the whole range of 0% through 100% of samples. This was only
partly explained by ER status and representation of genes by different platforms. Notably, a
larger proportion of samples from neoadjuvant studies were associated with a significant p-
value. We hypothesized that the p-value derived by CIBERSORT, which tests the null hypothe-
sis that none of the cells that comprise the signature matrix are present in a given sample [14],
would reflect the proportion of a sample that comprises immune cells versus non-immune
cells, where a greater proportion of non-immune cells would produce a correspondingly larger
p-value. We tested this hypothesis against another in silico metric of inflammation (immune
cytolytic activity [20]) in the two largest datasets: TCGA and METABRIC. Cytolytic activity
has previously been defined by Rooney et al. as the geometric mean of GZMA and PRF1
expression [20]. For TCGA we used cytolytic activity as computed by Rooney et al. For
METABRIC we computed the geometric mean based on GZMK and PRF1 expression because
there was no probe for GZMA. However, GZMA and GZMK are highly correlated (Pearson
correlation = 0.93 in the TCGA dataset). Cytolytic activity was most strongly correlated with
the proportion of gamma-delta T cells (Pearson correlation = 0.51 in ER-positive and 0.49 in
ER-negative disease) and M1 macrophages (Pearson correlation = 0.57 in ER-positive and 0.39
in ER-negative disease) in the TCGA and METABRIC studies at a CIBERSORT p< 0.05 (S4
and S5 Figs). Fig 2B depicts the strong ordinal relationship between different p-value thresh-
olds and cytolytic activity in both the TCGA and METABRIC datasets. The relationship
between cytolytic activity and the empirical CIBERSORT p-value strongly suggests that the
p-value reflects the relative proportion of a sample composed of immune versus non-immune
cells. We further tested this hypothesis by exploring the association between p-value thresholds
and survival. Fig 2B shows that in ER-negative tumours, a p< 0.01, corresponding to a greater
proportion of immune cells, was associated with significantly improved survival (log-rank p<
0.0001), while a p 0.05 was associated with the poorest outcome, and p 0.01 but<0.05
showed an intermediate outcome, though not significantly different to that of the p 0.05
group (log-rank p = 0.2). In contrast, in ER-positive disease, survival time did not differ signi-
ficantly by the proportion of infiltrating immune cells as measured by CIBERSORT p-value
(pinteraction < 0.001). This interaction between the prognostic effect of immune cells and ER
status is well known [8,29,30], supporting the conclusion that CIBERSORT p-values reflect
proportions of immune versus non-immune cells.
Proportions of different immune cells were weakly to moderately correlated. S6 and S7 Figs
depict correlation matrices between immune cell subsets by ER status. Patterns of correlation
were broadly similar irrespective of ER status. Among ER-positive tumours, neutrophils and
natural killer cells showed the strongest positive correlation (Pearson correlation = 0.36), while
resting memory T cells and CD8+ T cells showed the strongest negative correlation (Pearson
correlation = −0.34). In ER-negative disease, T regulatory cells and CD8+ cells showed the
strongest positive correlation (Pearson correlation = 0.33), and, as for ER-positive tumours,
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resting memory T cells and CD8+ T cells showed the strongest negative correlation (Pearson
correlation = −0.33).
Prognostic Subsets of Immune Cells
Different immune cell subsets were associated with favourable outcome in ER-positive com-
pared to ER-negative disease (Fig 3). Fig 3A depicts the unadjusted HRs and 95% confidence
intervals for quartiles of cell type proportion by ER status. Restricting analyses to samples with
a CIBERSORT p< 0.05, there were 2,653 patients with a median follow-up of 6.2 y for ER-pos-
itive disease, with the type of follow-up being relapse-free survival for 759 patients (171
events), distant metastasis-free survival for 976 patients (278 events), disease-specific survival
for 529 patients (110 events), and overall survival for 389 patients (117 events). For ER-nega-
tive disease, there were 1,398 patients with a median follow-up of 4.4 y, with the type of follow-
up being relapse-free survival for 298 patients (78 events), distant metastasis-free survival for
524 patients (180 events), disease-specific survival for 321 patients (92 events), and overall sur-
vival for 255 patients (91 events). Eosinophils (pinteraction by ER status = 0.052) and monocytes
(pinteraction by ER status = 0.04) were significantly associated with improved outcome in ER-
positive disease, whereas CD4+ activated memory T cells (pinteraction by ER status = 0.2) and
CD8+ T cells (pinteraction by ER status = 0.03) were associated with improved outcome in ER-
negative disease. In general, however, T cells tended to be associated with favourable outcome
irrespective of ER status, though at varying significance. The exception to this general trend
was T regulatory cells, which were associated with poorer outcome in both ER-positive (HR
1.18, 95% CI 1.08–1.28; p< 0.001) and ER-negative (HR 1.17, 95% CI 1.06–1.30; p = 0.002)
disease, consistent with their proposed role as pro-tumourigenic immune suppressors [31,32].
Similarly, in ER-positive disease, both M0 and M2 macrophages were associated with poorer
outcome, with a similar pattern in ER-negative disease, though non-significant for M0 macro-
phages (p = 0.2). Of these, M2 macrophages are thought to have an immune-suppressive pro-
tumourogenic role [33,34]. Similar associations for M0 macrophages raise the possibility that
there is some functional overlap between these two subsets of macrophages in the context of
tumour-associated inflammation. Multivariable analyses adjusted for known prognostic fac-
tors revealed that in ER-positive disease (Table A in S1 Appendix), T regulatory cells (HR 1.15,
95% CI 1.04–1.26; p = 0.005), memory B cells (HR 0.92, 95% CI 0.84–1.00; p = 0.05), and M0
macrophages (HR 1.12, 95% CI 1.01–1.24; p = 0.04) all contributed to the model, with very simi-
lar imputed estimates (Table B in S1 Appendix). For comparison, Tables C and D in S1 Appen-
dix show these same models for ER-negative disease. In ER-negative disease, M2 macrophages
(HR 1.15, 95% CI 1.0–1.33; p = 0.05), CD8+ T cells (HR 0.87, 95% CI 0.75–1.00; p = 0.05), and
T regulatory cells (HR 1.2, 95% CI 1.06–1.35; p = 0.005) all contributed to the adjusted model
(Table E in S1 Appendix), with similar estimates based on multiple imputation, though CD8+ T
cells ceased to be significant (HR 0.92, 95% CI 0.82–1.02; p = 0.1; Table F in S1 Appendix). For
comparison, Tables G and H in S1 Appendix show these same models for ER-positive disease.
Based on CIBERSORT data, Gentles al. previously reported neutrophils and plasma cells to be
prognostic in both lung and breast cancer, with effects in opposing directions [35]. This obser-
vation was partly reproduced here insofar as the direction of effect was similar, with a greater
proportion of neutrophils associated with poorer outcome in ER-negative disease and a greater
proportion of plasma cells associated with better outcome in ER-positive disease (Fig 3). Tables
I and J in S1 Appendix depict multivariable Cox regression models with penalised maximum
likelihood estimation. Both models show attenuated but similar effects compared to the other
multivariable models, with T regulatory cells associated with the largest point estimates in both
ER-positive (HR = 1.13) and ER-negative disease (HR = 1.11).
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Variation in Prognostic Effect of Immune Cells by Molecular Subtype
We conducted exploratory subgroup analyses of the prognostic effect of all 22 immune cell
subsets by molecular subtype defined by ER and HER2, and by the IntClust classifier based on
genomic drivers [2] (S8 and S9 Figs). It should be noted that these two sets of subgroup analy-
ses (based on ER/HER2 and IntClust, respectively) divide the same data in two different ways.
Fig 3. Prognostic associations of subsets of immune cells. (A) Unadjusted HRs (boxes) and 95% confidence intervals (horizontal lines) limited
to cases with CIBERSORT p-value < 0.05. Box size is inversely proportional to the width of the confidence interval. Asterisks denote estimates with
a q-value < 0.05. (B) Survival plots of quartiles of immune cell subsets. Depicted p-values are from log-rank tests. ER, oestrogen receptor; HR,
hazard ratio; NK cells, natural killer cells.
doi:10.1371/journal.pmed.1002194.g003
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In subgroups defined by ER and HER2, significant heterogeneity of prognostic effect was
observed for four cell subsets, of which three were of myeloid lineage. Activated memory T
cells were associated with favourable outcome in all subgroups except ER+/HER2− tumours
(HR 1.0, 95% CI 0.92–1.08), with the largest effect observed in the ER−/HER2+ subgroup (HR
0.73, 95% CI 0.60–0.89; pheterogeneity = 0.022). In contrast, M0 macrophages were most strongly
associated with poorer outcome in the ER+/HER2− subgroup (HR 1.25, 95% CI 1.15–1.37;
pheterogeneity = 0.024) compared to the other subgroups. Most strikingly, both activated den-
dritic cells and neutrophils showed the greatest heterogeneity of prognostic effect: a strong
association with poor outcome in ER+/HER2+ tumours but not in the other subgroups. How-
ever, these cell types were not correlated in the ER+/HER2+ subgroup (Pearson correla-
tion = 0.08) or overall (Pearson correlation = 0.07). Specifically, among this subset of patients,
activated dendritic cells showed a strong association with poor outcome (HR 1.3, 95% CI
1.14–1.49), while in all other subgroups, including ER−/HER2+ tumours, the point estimate
was less than one (pheterogeneity = 0.0008). Similarly, neutrophils showed a clear association
with poor outcome in the context of ER+/HER2+ disease (HR 1.37, 95% CI 1.18–1.60) but not
in the other subgroups (pheterogeneity = 0.0007).
Among subgroups defined by IntClust classification, plasma cells and activated mast cells
showed significant heterogeneity of effect. Plasma cells were associated with favourable out-
come among some ER-positive subgroups (IntClust 4+, IntClust 8, and IntClust 7) but not
among other subgroups (pheterogeneity = 0.03), while activated mast cells were associated with
poorer outcome in IntClust 5 (HER2-positive disease), IntClust 8, and IntClust 9 but not oth-
ers (pheterogeneity = 0.03). These analyses warrant cautious interpretation as, despite a large over-
all sample size, they are relatively underpowered given the large number of subgroups.
Tumours Lacking Immune Infiltration
Previous reports of the association between different immune cell types and outcome in breast
cancer, including our large analysis of cytotoxic T cells [8], have generally found an association
of immune cell types with survival in ER-negative breast cancer and little or no association in
ER-positive breast cancer [8,36]. Our present findings partly contradicted these observations.
Previous studies, however, included tumours lacking immune cells as well as those that con-
tained them. Since our analyses were limited to tumours with at least moderate immune infil-
tration based on cytolytic activity (CIBERSORT p< 0.05), we hypothesized that comparison
to a different reference population, i.e., one limited to tumours with moderate to high infiltra-
tion of immune cells, might explain why our observations differed from those previously
reported. To test this hypothesis we undertook exploratory survival analyses where we investi-
gated the association between all 22 cell subsets and outcome across three overlapping popula-
tions: those with a CIBERSORT p< 0.01, those with a CIBERSORT p< 0.05, and all cases
irrespective of CIBERSORT p-value. For analyses of the whole population, cases with a p
0.05 were taken as a separate reference group since they showed very low immune cell infiltra-
tion based on cytolytic activity. Fig 4 depicts the results of these analyses. In general, we found
that in ER-negative disease, as the size of the population increased to include tumours with
low or no infiltration, the prognostic effect of the majority of immune cell types shifted toward
improved outcome, whereas in ER-positive disease, the shift was toward the null. This was
observed irrespective of whether the point estimate for the high infiltration (CIBERSORT p<
0.01) population was more or less than one to begin with: it fell closer to one in ER-positive
disease and fell below one in ER-negative disease. This finding indicates a general trend that
differs by ER status. In ER-positive disease, tumours lacking immune infiltration were associ-
ated with an outcome that was intermediate or similar to tumours with low or high infiltration,
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whereas in ER-negative disease, tumours lacking immune infiltration were associated with a
poorer outcome compared to tumours with infiltration, irrespective of its degree. This is fur-
ther illustrated in Fig 5, which depicts survival plots highlighting the population with tumours
showing low to no infiltration. We speculate that this finding may explain many of the contra-
dictory reports of the prognostic effect of different immune cell subsets in breast cancer, and
possibly in other solid tumours [37]. Moreover, it potentially has profound implications for
inclusion of immune infiltrates as part of clinical prognostic models.
Immune Predictors of Response to Chemotherapy
We used data from studies of neoadjuvant chemotherapy to assess the association between
subsets of immune cells and pCR to chemotherapy (Fig 6). pCR is associated with improved
survival, and this association is greatest in aggressive subtypes of breast cancer, which are
more often ER negative [23]. Therefore we conducted analyses separately by ER status. In ER-
negative tumours, T follicular helper cells (Tfh cells) showed the strongest association with
pCR (odds ratio [OR] 1.34, 95% CI 1.14–1.57; p< 0.001; pinteraction by ER status = 0.03), while
M2 macrophages showed the strongest association with a lack of pCR and, therefore, resis-
tance to chemotherapy (OR 0.78, 95% CI 0.66–0.92; p = 0.003; pinteraction by ER status = 0.02).
This may partly explain the association between M2 macrophages and poorer outcome in
ER-negative disease. Multivariate analysis in ER-negative disease (Table O in S1 Appendix)
revealed that both M2 macrophages (OR 0.75, 95% CI 0.58–0.96; p = 0.02) and resting mast
Fig 4. Hazard ratios for three overlapping populations defined by CIBERSORT p-value. Boxes represent hazard ratios, and vertical lines
are 95% confidence intervals. Box size is inversely proportional to the width of the confidence interval. ER, oestrogen receptor; NK cells, natural
killer cells.
doi:10.1371/journal.pmed.1002194.g004
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cells (OR 0.77, 95% CI 0.61–0.97; p = 0.03) contributed to the adjusted model in the complete
case analysis (n = 332), but estimates based on multiple imputation (Table P in S1 Appendix)
revealed that M2 macrophages (OR 0.83, 95% CI 0.96–1.00; p = 0.05), memory B cells (OR 1.2,
95% CI 1.01–1.42; p = 0.04), and Tfh cells (OR 1.31, 95% CI 1.11–1.56; p = 0.002) all contrib-
uted to the adjusted model (n = 566). In ER-positive disease, both memory B cells and mono-
cytes showed a strong association with a lack of pCR. However, in survival analyses, both these
cell types were associated with better rather than worse outcome. The basis of this apparent
contradiction in ER-positive breast cancer is not known, and pCR has not been generally
accepted as an endpoint for assessing the effectiveness of chemotherapy in ER-positive disease
[23]. Estimates based on multivariable models with penalised maximum likelihood estimation
did not show any associations between the 26 predictors and pCR. This is likely to be related,
in part, to the modest power of these models relative to the number of predictors.
Immune Clusters Associated with Outcome and Patient Age
We investigated whether distinct patterns of immune infiltration could be discerned based on
the 22 immune cell proportions by conducting hierarchical clustering of all samples. We
Fig 5. Survival plots highlighting the patient subgroup with tumours containing little or no immune infiltration by CIBERSORT p-value.
Depicted p-values are from log-rank tests. ER, oestrogen receptor; T-regs, T regulatory cells.
doi:10.1371/journal.pmed.1002194.g005
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interpreted the Duda-Hart index and the associated pseudo-T-squared statistic to indicate
eight clusters in the data (S10 Fig). Cell proportions by cluster are depicted in Fig 7, and their
distributions as box plots in S11 and S12 Figs. Clusters were associated with distinct patterns
Fig 6. Association between immune cell subsets and response to neoadjuvant chemotherapy. (A) Boxes represent ORs from
unadjusted logistic regression models. Horizontal lines are 95% confidence intervals. Box size is inversely proportional to the width of the
confidence interval. Asterisks denote estimates with q-value < 0.05. (B) Spine plots depicting the association between quartiles of immune cell
subsets and pCR. ER, oestrogen receptor; NK cells, natural killer cells; OR, odds ratio; pCR, pathological complete response.
doi:10.1371/journal.pmed.1002194.g006
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of survival in ER-positive and ER-negative disease (Fig 8). Cluster 7, defined by high levels of
M0 and M2 macrophages, and cluster 8, defined by a high level of M2 macrophages though
relatively low level of M0 and M1 macrophages, were both associated with poor outcome in
ER-negative and ER-positive disease. In contrast, cluster 5, defined by moderate levels of M0
and M1 macrophages and plasma cells and a high level of resting memory T cells, was associ-
ated with poor outcome in ER-negative tumours but with the best outcome in ER-positive dis-
ease. Clusters were significantly, but modestly, associated with ER status (p< 0.001) and with
Fig 7. Hierarchical clustering of all samples based on immune cell proportions. Stacked bar charts of samples ordered by cluster assignment. NK cells,
natural killer cells.
doi:10.1371/journal.pmed.1002194.g007
Fig 8. Survival plots by cluster separately for ER-positive and ER-negative disease. Depicted p-values are from log-rank tests. ER, oestrogen
receptor.
doi:10.1371/journal.pmed.1002194.g008
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IntClust subtype (p< 0.001; S13 Fig). The association with ER status was largely due to clusters
3 and 4. Cluster 3 was particularly enriched for ER-positive tumours (77% compared to 62%
overall), while cluster 4 was enriched for ER-negative tumours (45% compared to 38% overall).
Immune clusters were also associated with patient age in ER-positive disease (p< 0.001),
with a weak association in ER-negative disease (p = 0.05). Women with ER-positive tumours
assigned to cluster 1 (defined by high levels of neutrophils and CD8+ T cells) were on average
53 y old at diagnosis, while those with tumours assigned to cluster 3 (defined by high levels
of M2 macrophages, CD8+ T cells, and plasma cells) were on average 60 y old. Collectively,
these findings suggest that there is considerable variability in the nature of the immune infil-
trate across breast tumours—partly determined by molecular characteristics of the primary
tumour—and that this influences clinical outcome.
Discussion
Based on deconvolution of bulk gene expression data from nearly 11,000 cases of breast cancer,
we uncovered distinct patterns of immune infiltration between tumours, complex associations
with clinical outcome for different subsets of immune cells that depend on ER status, and
immune mediators of both sensitivity and resistance to chemotherapy.
Advances in computational methods have reinvigorated the potential of large public reposi-
tories of genomic data collected over the past two decades. Using a state-of-the-art deconvolu-
tion algorithm, CIBERSORT [14], to infer the proportions of 22 immune cell subsets from
tumour transcriptomes, we have conducted, to our knowledge, the most comprehensive
analysis of the clinical impact of the immune response in breast cancer to date. We found that
some immune suppressor cells (T regulatory cells and M2 macrophages) were associated with
poorer outcome but that M0 macrophages too showed similar associations with survival.
Previous experiments have shown that tumours may attract T regulatory cells to evade the
immune response [31,32], and although subsets of T regulatory cells with different functions
in cancer continue to be discovered [38], our findings support the tumour-promoting role of
T regulatory cells. The distinction between “polarised states” of macrophages is, however, the
subject of some dispute [34]. The M1 (activated; anti-tumoural) and M2 (alternatively acti-
vated; pro-tumoural) phenotypes are associated with distinct immunoregulatory functions,
but it has been argued that they represent extremes of a spectrum of functional states rather
than truly distinct cell types [34]. Tumours are likely to contain macrophages in a variety of
such states, and our finding of an association between M0 macrophages and poorer outcome
may reflect this gradation of function. We also found that the proportions of M0, M1, and M2
macrophages defined several immune cell signatures in our clustering analysis, with prognos-
tic implications. Moreover, higher proportions of M2 macrophages were associated with a
lack of response to chemotherapy in ER-negative tumours, suggesting that they may mediate
resistance mechanisms—a conclusion supported by previous preclinical experiments [39].
Collectively, these findings demonstrate the potential of tumour-associated macrophages as
biomarkers in breast cancer. In particular, they highlight the necessity of accounting for the
diversity of macrophages’ functional states rather than treating them all equally. This is of spe-
cial importance because treatments to combat the tumour-promoting roles of macrophages
are already in early phase clinical trials [40]. These approaches block colony stimulating factor
1 (CSF1) signalling by targeting colony stimulating factor 1 receptor (CSF1R) [39,41]. Preclini-
cal evidence also supports the potential of CSF1R inhibition in breast cancer in conjunction
with conventional chemotherapy [39]. Inhibition of CSF1R has been shown not to kill macro-
phages but to lead to a change in their functional state to a state thought to be anti-tumoural
[34,42]. In this respect, this approach might be considered a differentiation therapy of the
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tumour microenvironment, again emphasising the need for practical biomarkers that account
for the variety of functional states of macrophages in cancer tissue.
We also found Tfh cells to be strongly associated with response to chemotherapy in ER-neg-
ative breast cancer. Tfh cells play an important role in the maintenance and development of
germinal centres and the selective evolution of high-affinity plasma cells and memory B cells
from antigen-specific B cells. They have not been widely investigated in solid tumours, but,
based on genomic and histological analyses, they have recently been shown to play a role in
breast tumours with extensive immune infiltration and, in particular, in the response to che-
motherapy [43]. Whether this effect is exerted through tumour-specific antibody-dependent
mechanisms is uncertain, but there is some evidence for tumour-antigen-specific responses by
B cells in breast cancer [44,45], as well as observations of an association between plasma cells
and outcome across solid tumours [35,46,47]. Moreover, the fact that cross-reactive antibodies
targeting tumour neoepitopes underpin some paraneoplastic syndromes such as scleroderma
[48] strongly implies that tumour-antigen-specific antibody production can be part of the host
response to tumours. The presence of Tfh cells in breast cancer was also shown to be a reliable
indicator of an organised immune response including tertiary lymphoid structures [43]. Our
findings further support this observation since memory B cells were also associated with
response to chemotherapy in ER-negative tumours (Fig 6), with the strength of the association
second only to that of Tfh cells. In the clinical setting, these findings lend support to the use of
tumour-infiltrating lymphocytes as predictors of response to neoadjuvant chemotherapy but
also suggest that specifically accounting for the abundance of Tfh cells in dense immune infil-
trates may substantially improve predictive accuracy.
We found that tumours with little or no immune infiltration showed fundamental differ-
ences in patterns of patient survival based on ER status. In ER-negative disease, these tumours
were associated with poorer outcome compared to tumours with immune infiltration regard-
less of immune cell subset. Poorer outcome in patients with tumours that have failed to evince
an immune infiltrate is consistent with the idea that, in general, the immune response is
tumouricidal, albeit variably effective depending on its context and composition. For example,
increasing proportions of M0 macrophages were associated with poorer outcome, but the group
lacking immune infiltration was associated with survival poorer than that of patients with
tumours in the highest quartile of M0 macrophage proportion, rather than better survival than
the group in the first quartile, which is what might be expected if the association of survival with
M0 macrophages followed a strictly ordinal pattern. Whether these ER-negative tumours lack-
ing an immune infiltrate have been extensively immunoedited [49] and are therefore no longer
immunogenic, whether they enact an alternative approach to evade immune infiltration, or
whether the host is not able to mount an immune response is unknown. However, their natural
history appears consistent with the view of the immune response as an extrinsic tumour sup-
pressor, in contrast to the findings in the group of ER-positive tumours that lack immune infil-
tration. This group was not associated with a survival pattern easily explained by the immune
response. Women with ER-positive tumours lacking immune infiltration had a survival out-
come intermediate between that of women with tumours with high and low infiltration, irre-
spective of cell type. This observation is more suggestive of tumours that do not evince an
immune response from conception rather than of immunoedited tumours. It also implies
that tumours lacking an immune response are not next in sequence to those with a minimal
response but differ more fundamentally, and should be excluded from relevant biomarker anal-
yses. Finally, this group of patients is likely to gain the least from new immune checkpoint inhib-
itors unless a way of inducing an effective immune response is coupled with this approach.
Previous immune profiling studies in breast cancer have used either genomic data or in situ
histological analyses to quantify the immune response [8,29,36,50,51]. These approaches have
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confirmed the prognostic significance of the immune response, particularly in ER-negative dis-
ease, but have been of limited resolution, often including only one or two cell types. While this
has enabled very large scale analyses and candidate clinical assay development, much of the func-
tional variation implicit in the immune response, and its clinical importance, is missed. Studies
using multiparametric flow cytometry and immunofluorescence have produced an expanded,
but still limited, view of the immune response at cellular resolution [52], but have been restricted
to very small sample sizes, precluding analysis of association with clinical outcome. One recent
analysis of genomic data also deconvolved tumour transcriptomes to estimate the presence of
230 murine haematopoietic lineage profiles, generating “cell lineage scores” for patients, and
investigated their association with outcome [53]. While an important advance on previous work,
this approach has not been as extensively validated as CIBERSORT, and the analysis comprised
a much smaller sample size than the present work and did not directly address associations with
treatment response. Recent pan-cancer analyses using quantitative genomic approaches have
also uncovered important associations between immune cell subsets and survival across tumour
types [35,54]. Our study further advances knowledge of the clinical impact of the immune
response, particularly highlighting diverse associations with outcome related to different func-
tional cell subsets and, importantly, accounts for the significance of molecular subtype.
This was a large analysis of tumour samples from a great breadth of studies in which we
enumerated the immune response in detail. Our conclusions are likely, therefore, to be reliable
and generalizable. This is the main strength of the study; however, in increasing our sample
size we made use of historic studies, some of which were profiled using platforms not formally
validated for use with CIBERSORT, which is the main limitation of this work. Therefore, the
reliability of the inferred immune infiltrate in some studies is uncertain. Similarly, in our effort
to derive precise and reliable estimates of association with clinical outcome, we collated diverse
and heterogeneous studies with different types of follow-up, which is a second limitation. While
this is not ideal, it should be noted that relapse or metastasis is highly correlated with disease-
specific survival, and our conclusions are substantially more reliable because our approach
increased statistical power. A large proportion of patients who experience disease relapse or
metastasis will ultimately succumb to their disease, though at a later time point, which, all other
factors being equal, may attribute slightly greater weight to relapse-free or metastasis-free sur-
vival. It is likely that this effect will be larger for ER-positive disease because patients with meta-
static ER-positive breast cancer tend to experience longer survival than those with ER-negative
breast cancer. Another related limitation is the relatively short average follow-up for each
patient: the median follow-up was 6.2 y for ER-positive patients and 4.4 y for ER-negative
patients. For both subsets this falls short of capturing all disease-related events. Patients with ER-
positive disease continue to experience relapse well beyond 10 y, while those with ER-negative
disease invariably experience relapse within the first 5 y [21], and some of these events were not
represented in this analysis. While the diversity of studies included in the analysis increases the
generalizability our findings, it is also a limitation insofar as patients are likely to have experi-
enced differences in clinical care owing to differences in date of diagnosis, clinical setting, geog-
raphy, and treatment. It is, however, unlikely that these differences affected the inferred immune
cell populations of primary tumours; if anything, these differences are likely to diminish associa-
tions between the immune response and clinical outcome, raising the possibility that our obser-
vations underestimate these effects and may include false negatives. Finally, the associations
reported here arise from discovery analyses and require validation in independent studies.
Our analysis of 22 immune cell subsets in breast cancer has revealed important associations
with clinical outcome that have the potential to identify patients who could benefit from
immunotherapies, as well as highlighting possible targets for new drugs. Coupling reliable
deconvolution algorithms with large-scale genomic data has the potential to further uncover
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the clinical and biological significance of the plethora of non-cancer cells that comprise the
tumour microenvironment in breast cancer.
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